Market Place
Sourcing Support
Data Support Vutrisiran In ATTR-CM Zilebesiran HTN Management
30 Mar 2026 //
BUSINESSWIRE
Alnylam, Viz.ai Partner To Advance ATTR-CM Care
24 Mar 2026 //
BUSINESSWIRE
Tenaya, Alnylam Ink Collab to Find Gene Targets For Cardio Drugs
05 Mar 2026 //
FIERCE BIOTECH
Alnylam To Present At TD Cowen 46Th Health Care Conference
23 Feb 2026 //
BUSINESSWIRE
Alnylam To Present At 44Th J.P. Morgan Healthcare Conference
05 Jan 2026 //
BUSINESSWIRE
PeptiDream, Alnylam Reach Milestone In Targeted Sirna Delivery
18 Dec 2025 //
BUSINESSWIRE
Alnylam Drafts $250 M Upgrade to Its Mass. Drug Factory
18 Dec 2025 //
BUSINESSWIRE
Alnylam Buys Back Part of 1.00% Convertible Senior Notes Due 2027
11 Dec 2025 //
BUSINESSWIRE
Vutrisiran Enhances Heart Structure And Function In ATTR-CM
08 Nov 2025 //
BUSINESSWIRE
Alnylam To Present At November Investor Conferences
04 Nov 2025 //
BUSINESSWIRE
Alnylam Pharma Reveals Q3 2025 Financials and Recent Progress
30 Oct 2025 //
BUSINESSWIRE
Alnylam Doses First Patient in Ph3 ZENITH Zilebesiran Trial
01 Oct 2025 //
BUSINESSWIRE
HELIOS-B Ph 3 Shows Lower GI Events In ATTR-CM With Vutrisiran
28 Sep 2025 //
BUSINESSWIRE
Moderna, Alnylam Settle COVID-19 Vaccine Patent Dispute
19 Sep 2025 //
FIERCE PHARMA
Moderna Settles Alnylam Patent Lawsuits Over Covid Vaccine
19 Sep 2025 //
REUTERS
Alnylam Pharma Joins Alliance for Genomic Discovery to Expand
18 Sep 2025 //
PR NEWSWIRE
Alnylam Prices Upsized $575 M Convertible Senior Notes Offering
09 Sep 2025 //
BUSINESSWIRE
Alnylam Proposes $500 Million Convertible Senior Notes Offering
08 Sep 2025 //
BUSINESSWIRE
HELIOS-B Phase 3 Study Presented at ESC Congress 2025
31 Aug 2025 //
BUSINESSWIRE
Roche, Alnylam to Initiate Phase 3 Trial of Zilebesiran
31 Aug 2025 //
PRESS RELEASE
Scenic Enters License and Research Agreement with Alnylam
26 Aug 2025 //
GLOBENEWSWIRE
Alnylam Showcases RNAi Therapeutics for Cardiovascular Disease
11 Aug 2025 //
BUSINESSWIRE
Alnylam`s Market Cap Jumps Past $50 B
01 Aug 2025 //
FIERCE PHARMA
Alnylam Receives European Commission Approval for Amvuttra
10 Jun 2025 //
BIOSPACE
Alnylam Issues 2024 Corporate Responsibility Report
20 May 2025 //
BUSINESSWIRE
AMVUTTRA® (vutrisiran) Reduces Mortality and Cardiovascular Event
17 May 2025 //
BUSINESSWIRE
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech
14 May 2025 //
REUTERS
Alnylam to Present HELIOS-B Data at Heart Meeting
12 May 2025 //
BUSINESSWIRE
Alnylam Gets CHMP Backing for Vutrisiran in ATTR-CM
28 Apr 2025 //
BUSINESSWIRE
Alnylam to Webcast at Needham 24th Annual Healthcare Conference
01 Apr 2025 //
BUSINESSWIRE
Alnylam Announces Retirement Of Co-Founder Dr. Phillip A. Sharp
05 Mar 2025 //
BUSINESSWIRE
Alnylam Announces 2024 Revenues & 2025 Guidance With Pipeline Goals
12 Jan 2025 //
BUSINESSWIRE
Alnylam Announces Nucresiran Phase 1 Data on TTR Knockdown
17 Nov 2024 //
BUSINESSWIRE
Alnylam to Webcast Conference Discussing Q3 2024 Financial Results
17 Oct 2024 //
BUSINESSWIRE
Alnylam Submits Application For Vutrisiran In ATTR Amyloidosis
16 Oct 2024 //
BUSINESSWIRE
Alnylam Submits sNDA to FDA For Vutrisiran In ATTR-CM
09 Oct 2024 //
BUSINESSWIRE
Alnylam drops patent lawsuit against Moderna over Covid-19 vaccine
07 Oct 2024 //
ENDPTS
Alnylam: New Data From HELIOS-B Study At Heart Failure Meeting
29 Sep 2024 //
BUSINESSWIRE
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Alnylam Reports Q2 2024 Results And Recent Highlights
01 Aug 2024 //
BUSINESSWIRE
Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
20 Apr 2024 //
PHARMABIZ
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran
07 Apr 2024 //
BUSINESSWIRE
Alnylam to Webcast to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran
20 Mar 2024 //
BUSINESSWIRE
Alnylam Presents Results from the KARDIA-1 Phase 2 Study of Zilebesiran
13 Nov 2023 //
BUSINESSWIRE
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP
25 Oct 2023 //
BUSINESSWIRE
Alnylam Announces Publication of Results from Phase 3 Study of Patisiran
25 Oct 2023 //
BUSINESSWIRE
Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran
13 Oct 2023 //
SEEKING ALPHA
Alnylam to Present Data for Patisiran in Patients With ATTR Amyloidosis
06 Oct 2023 //
PRESS RELEASE
Alnylam Announces Positive Outcome of Advisory Committee Meeting on Patisiran
13 Sep 2023 //
BUSINESSWIRE
FDA questions efficacy of Alnylam`s patisiran in disabling ATTR-CM
12 Sep 2023 //
ENDPTS
Alnylam Reports Positive Results from Phase 2 Dose-Ranging Study of Zilebesiran
07 Sep 2023 //
BUSINESSWIRE
Alnylam plans to appeal Covid-19 vaccine patent ruling in case against Moderna
28 Aug 2023 //
ENDPTS
Alnylam to appeal ruling on patents related to Moderna`s COVID vaccines
26 Aug 2023 //
REUTERS
Agios pays $17.5M for Alnylam`s siRNA blood disease program
03 Aug 2023 //
FIERCE BIOTECH
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran
19 Jul 2023 //
BUSINESSWIRE
Alnylam, Regeneron`s RNAi therapeutic continues to show benefit in Alzheimer`s Disease
18 Jul 2023 //
PRESS RELEASE
Alnylam Files COVID-19 Vaccine Infringement Lawsuits Against Pfizer and Moderna
02 Jun 2023 //
JDSUPRA
Alnylam files yet another patent suit against Pfizer and Moderna
31 May 2023 //
FIERCE PHARMA
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran
20 May 2023 //
BUSINESSWIRE
Moderna hits back at Alnylam`s `baseless` infringement claims
17 May 2023 //
FIERCE PHARMA
